CLAIMS

1. A compound of the formula I:



(I)

wherein:

Z is -NH-, -O- or -S-;

R^1 represents bromo or chloro;

R^3 represents C_{1-3}alkoxy or hydrogen;

R^2 is selected from one of the following three groups:

(i) Q^1X^1-

wherein X^1 represents -O-,-S- or -NR^4- wherein R^4 is hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and Q^1 is selected from one of the following ten groups:

1) Q^2 (wherein Q^2 is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy

and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl),

or Q^2 bears a single substituent selected from methylenedioxy and ethylenedioxy);

with the proviso that if Q^1 is Q^2 and X^1 is -O- then Q^2 must bear at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and optionally may bear a further 1 or 2 substituents as defined herein;

2) C_{1-5}alkylW^1Q^2 (wherein W^1 represents -O-, -S-, -SO-, -SO_2-, -C(O)-, -OC(O)-, -NQ^3C(O)-, -C(O)NQ^4-, -SO_2NQ^5-, -NQ^6SO_2- or –NQ^7- (wherein Q^3, Q^4, Q^5, Q^6 and Q^7 each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein;

3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);

4) C_{2-5}alkenylQ^2 (wherein Q^2 is as defined herein);

5) C_{2-5}alkynylQ^2 (wherein Q^2 is as defined herein);

6) C_{1-4}alkylW^2C_{1-4}alkylQ^2 (wherein W^2 represents -O-, -S-, -SO-, -SO_2-, -C(O)-, -OC(O)- -NQ^8C(O)-, -C(O)NQ^9-, -SO_2NQ^{10}-, -$NQ^{11}SO_2$- or –NQ^{12}- (wherein Q^8, Q^9, Q^{10}, Q^{11} and Q^{12} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein);

7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

9) C_{1-4}alkylQ^{13}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{14}$ (wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-}

$_4$alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the provisos that Q^{13} cannot be hydrogen and one or both of Q^{13} and Q^{14} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein); and

10) C_{1-4}alkylQ^{13}-C(O)-C_{1-4}alkylQ^{14n} wherein Q^{13} is as defined herein and is not hydrogen and Q^{14n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further heteroatom selected from N and O wherein Q^{14n} is linked to C_{1-6}alkyl via a nitrogen atom or a carbon atom and wherein Q^{14n} optionally bears 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl)
or Q^{14n} bears a single substituent selected from methylenedioxy and ethylenedioxy);

(ii) $Q^{15}W^3$-

wherein W^3 represents $-NQ^{16}C(O)-$, $-C(O)NQ^{17}-$, $-SO_2NQ^{18}-$, $-NQ^{19}SO_2-$ or $-NQ^{20}-$ (wherein Q^{16}, Q^{17}, Q^{18}, Q^{19} and Q^{20} each independently represents C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}haloalkyl), and Q^{15} is C_{1-6}haloalkyl, C_{2-5}alkenyl or C_{2-5}alkynyl; and

(iii) $Q^{21}W^4C_{1-5}$alkylX^1 wherein X^1 is as defined herein, W^4 represents $-NQ^{22}C(O)-$, $-C(O)NQ^{23}-$, $-SO_2NQ^{24}-$, $-NQ^{25}SO_2-$ or $-NQ^{26}-$ (wherein Q^{22}, Q^{23}, Q^{24}, Q^{25} and Q^{26} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl), and Q^{21} represents C_{1-6}haloalkyl, C_{2-5}alkenyl or C_{2-5}alkynyl;

or a salt thereof.

2. A compound according to claim 1 wherein Z is -NH-.

3. A compound according to claim 1 or claim 2 wherein R^3 is methoxy.

4. A compound according to any one of claims 1, 2 and 3 wherein X^1 is -O-.

5. A compound according to any one of the preceding claims wherein R^2 is selected from group (ii) of the groups (i), (ii) and (iii) defined in claim 1.

6. A compound according to any one of the preceding claims wherein R^2 is selected from group (iii) of the groups (i), (ii) and (iii) defined in claim 1.

7. A compound according to any one of the preceding claims wherein R^2 is selected from group (i) of the groups (i), (ii) and (iii) defined in claim 1.

8. A compound according to claim 7 wherein R^2 is Q^1X^1- wherein X^1 is as defined in claim 1 and Q^1 is selected from one of the following ten groups:

1) Q^2 (wherein Q^2 is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl,

C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl),

or Q^2 bears a single substituent selected from methylenedioxy and ethylenedioxy);

with the proviso that if Q^1 is Q^2 and X^1 is -O- then Q^2 must bear at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and optionally may bear a further 1 or 2 substituents as defined herein;

2) C_{1-5}alkylW^1Q^2 (wherein W^1 represents -O-, -S-, -SO-, -SO_2-, -C(O)-, -OC(O)-, -NQ^3C(O)-, -C(O)NQ^4-, -SO_2NQ^5-, -NQ^6SO_2- or –NQ^7- (wherein Q^3, Q^4, Q^5, Q^6 and Q^7 each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein;

3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);

4) C_{2-5}alkenylQ^2 (wherein Q^2 is as defined herein);

5) C_{2-5}alkynylQ^2 (wherein Q^2 is as defined herein);

6) C_{1-4}alkylW^2C_{1-4}alkylQ^2 (wherein W^2 represents -O-, -S-, -SO-, -SO_2-, -C(O)-, -OC(O)- -NQ^8C(O)-, -C(O)NQ^9-, -SO_2NQ^{10}-, -$NQ^{11}SO_2$- or –NQ^{12}- (wherein Q^8, Q^9, Q^{10}, Q^{11} and Q^{12} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein);

7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

9) C_{1-4}alkylQ^{13}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{14}$ (wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2

heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the provisos that Q^{13} cannot be hydrogen and one or both of Q^{13} and Q^{14} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein); and

10) C_{1-4}alkylQ^{13}-C(O)-C_{1-4}alkylQ^{14n} wherein Q^{13} is as defined herein and is not hydrogen and Q^{14n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further heteroatom selected from N and O wherein Q^{14n} is linked to C_{1-6}alkyl via a nitrogen atom and wherein Q^{14n} optionally bears 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino,

di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl)
or Q^{14n} bears a single substituent selected from methylenedioxy and ethylenedioxy).

9. A compound according to claim 7 wherein R^2 is Q^1X^1- wherein X^1 is as defined in claim 1 and Q^1 is selected from one of the following ten groups:

1) Q^2 (wherein Q^2 is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl),
or Q^2 bears a single substituent selected from methylenedioxy and ethylenedioxy);
with the proviso that if Q^1 is Q^2 and X^1 is -O- then Q^2 must bear at least one substituent selected from C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and optionally may bear a further 1 or 2 substituents as defined herein;

2) C_{1-5}alkylW^1Q^2 (wherein W^1 represents -O-, -S-, -SO-, $-SO_2-$, -C(O)-, -OC(O)-, $-NQ^3C(O)-$, $-C(O)NQ^4-$, $-SO_2NQ^5-$, $-NQ^6SO_2-$ or $-NQ^7-$ (wherein Q^3, Q^4, Q^5, Q^6 and Q^7 each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein;

3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);

4) C_{2-5}alkenylQ^2 (wherein Q^2 is as defined herein);

5) C_{2-5}alkynylQ^2 (wherein Q^2 is as defined herein);

6) C_{1-4}alkylW^2C_{1-4}alkylQ^2 (wherein W^2 represents -O-, -S-, -SO-, $-SO_2-$, -C(O)-, -OC(O)- $-NQ^8C(O)-$, $-C(O)NQ^9-$, $-SO_2NQ^{10}-$, $-NQ^{11}SO_2-$ or $-NQ^{12}-$ (wherein Q^8, Q^9, Q^{10}, Q^{11} and Q^{12} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein);

7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined herein);

9) C_{1-4}alkyl$Q^{13}(C_{1-4}$alkyl$)_j(W^2)_kQ^{14}$ (wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the proviso that one or both of Q^{13} and Q^{14} bears at least one substituent selected from aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein); and

10) C_{1-4}alkylQ^{13}-C(O)-C_{1-4}alkylQ^{14n} wherein Q^{13} is as defined herein and Q^{14n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further heteroatom selected from N and O wherein Q^{14n} is linked to C_{1-6}alkyl via a nitrogen atom or a carbon atom and wherein Q^{14n} optionally bears 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl) or Q^{14n} bears a single substituent selected from methylenedioxy and ethylenedioxy).

10. A compound according to claim 1 of the formula Ia:



(Ia)

wherein:

Za is -NH-, -O- or -S-;

R^{1a} represents bromo or chloro;

R^{3a} represents C_{1-3}alkoxy or hydrogen;

X^{1a} represents -O-,-S- or -NR^{4a}- wherein R^{4a} is hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl;

R^{2a} is selected from one of the following groups:

1) C_{1-5}alkylR^{5a} (wherein R^{5a} is a 5- or 6-membered heterocyclic ring selected from morpholine, pyrrolidine, piperidine and piperazine which heterocyclic ring bears at least one substituent selected from aminoC_{2-4}alkanoyl, C_{1-4}alkylaminoC_{2-4}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-4}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-4}alkanoyl, methylenedioxy and ethylenedioxy);

2) C_{2-5}alkenylR^{5a} (wherein R^{5a} is as defined herein);

3) C_{2-5}alkynylR^{5a} (wherein R^{5a} is as defined herein);

4) C_{1-5}alkyl$R^{6a}C(O)(CH_2)_{ma}R^{7a}$ (wherein ma is 1 or 2, R^{6a} is a 5- or 6-membered heterocyclic ring selected from morpholine, pyrrolidine, piperidine and piperazine which heterocyclic ring may bear one or two substituents selected from fluoro, hydroxy and methyl, and R^{7a} is a 5- or 6-membered heterocyclic ring selected from pyrrolidine, piperidine, piperazine and morpholine which heterocyclic ring is linked to $(CH_2)_{ma}$ via a nitrogen atom or a carbon atom and which heterocyclic ring may bear one or more substituents selected from hydroxy, halogeno, C_{1-4}alkanoyl, methylenedioxy and ethylenedioxy); and

5) C_{1-5}alkyl$R^{6a}(CH_2)_{ma}C(O)R^{8a}$ (wherein ma and R^{6a} are as defined herein and R^{8a} is a 5- or 6-membered heterocyclic ring selected from pyrrolidine, piperidine, piperazine and morpholine which heterocyclic ring is linked to C(O) via a nitrogen atom or a carbon atom and which heterocyclic ring may bear one or more substituents selected from hydroxy, halogeno, C_{1-4}alkanoyl, methylenedioxy and ethylenedioxy)

or a salt thereof.

11. A compound according to claim 1 of the formula Ib:



(Ib)

wherein:

Z, R^1 and R^3 are as defined in claim 1 and

R^{2b} is selected from one of the following three groups:

(i) $Q^{1b}X^1$-

wherein X^1 is as defined in claim 1 and Q^{1b} is selected from one of the following ten groups:

1) Q^{2b} (wherein Q^{2b} is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl),
or Q^{2b} bears a single substituent selected from methylenedioxy and ethylenedioxy);
with the proviso that if Q^{1b} is Q^{2b} and X^1 is -O- then Q^{2b} must bear at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and optionally may bear a further 1 or 2 substituents as defined herein;

2) C_{1-5}alkylW^1Q^2 (wherein W^1 and Q^2 are as defined in claim 1);

3) C_{1-5}alkylQ^{2b} (wherein Q^{2b} is as defined herein);

4) C_{2-5}alkenylQ^2 (wherein Q^2 is as defined in claim 1);

5) C_{2-5}alkynylQ^2 (wherein Q^2 is as defined in claim 1);

6) C_{1-4}alkylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined in claim 1);

7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined in claim 1);

8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2 (wherein W^2 and Q^2 are as defined in claim 1);

9) C_{1-4}alkylQ^{13b}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{14b}$ (wherein W^2 is as defined in claim 1, j is 0 or 1, k is 0 or 1, and Q^{13b} and Q^{14b} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the provisos that Q^{13b} cannot be hydrogen and one or both of Q^{13b} and Q^{14b} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein); and

10) C_{1-4}alkylQ^{13}-C(O)-C_{1-4}alkylQ^{14n} (wherein Q^{13} and Q^{14n} are as defined in claim 1);

(ii) $Q^{15}W^3$- (wherein W^3 and Q^{15} are defined in claim 1); and

(iii) $Q^{21}W^4C_{1-5}$alkylX^1 (wherein X^1, W^4 and Q^{21} are as defined in claim 1);

or a salt thereof.

12. A compound according to claim 11 wherein R^{2b} is $Q^{1b}X^1$-

wherein X^1 is as defined in claim 1 and Q^{1b} is selected from one of the following ten groups:

1) Q^{2b} (wherein Q^{2b} is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl),
or Q^{2b} bears a single substituent selected from methylenedioxy and ethylenedioxy);
2) C_{1-5}alkylW^1Q^{2b} (wherein W^1 is as defined in claim 1 and Q^{2b} is as defined herein);
3) C_{1-5}alkylQ^{2b} (wherein Q^{2b} is as defined herein);
4) C_{2-5}alkenylQ^{2b} (wherein Q^{2b} is as defined herein);
5) C_{2-5}alkynylQ^{2b} (wherein Q^{2b} is as defined herein);
6) C_{1-4}alkylW^2C_{1-4}alkylQ^{2b} (wherein W^2 is as defined in claim 1 and Q^{2b} is as defined herein);
7) C_{2-5}alkenylW^2C_{1-4}alkylQ^{2b} (wherein W^2 is as defined in claim 1 and Q^{2b} is as defined herein);
8) C_{2-5}alkynylW^2C_{1-4}alkylQ^{2b} (wherein W^2 is as defined in claim 1 and Q^{2b} is as defined herein);
9) C_{1-4}alkylQ^{13b}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{14b}$ (wherein W^2 is as defined in claim 1, j is 0 or 1, k is 0 or 1, and Q^{13b} and Q^{14b} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-}

$_6$alkanoyl, aminoC_{2-6}alkanoyl, C_{1-4}alkylaminoC_{2-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{2-6}alkanoyl, C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the provisos that Q^{13b} cannot be hydrogen and one or both of Q^{13b} and Q^{14b} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein); and

10) C_{1-4}alkylQ^{13b}-C(O)-C_{1-4}alkylQ^{14b} (wherein Q^{13b} and Q^{14b} are as defined herein and with the provisos that Q^{13b} cannot be hydrogen and one or both of Q^{13b} and Q^{14b} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{1-4}alkoxyC_{1-4}alkylaminoC_{2-6}alkanoyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl and di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein).

13. A compound according to claim 1 selected from:

4-(4-bromo-2-fluoroanilino)-7-({1-[(*N*,*N*- dimethylamino)acetyl]piperidin-4-yl}methoxy)-6-methoxyquinazoline,

4-(4-chloro-2-fluoroanilino)-7-({1-[(*N*,*N*-dimethylamino)acetyl]piperidin-4-yl}methoxy)-6-methoxyquinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-{[1-(piperidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]methoxy}quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-({1-[(3a*R*,6a*S*)-tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-ylacetyl]piperidin-4-yl}methoxy)quinazoline,
7-({1-[(4-acetylpiperazin-1-yl)acetyl]piperidin-4-yl}methoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline,
(3*S*)-4-(4-chloro-2-fluoroanilino)-7-({1-[(3-hydroxypyrrolidin-1-yl)acetyl]piperidin-4-yl}methoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[(1-{[*N*-(2-methoxyethyl)amino]acetyl}piperidin-4-yl)methoxy]quinazoline,
4-(4-chloro-2-fluoroanilino)-6-methoxy-7-({1-[(*N*-methylamino)acetyl]piperidin-4-yl}methoxy)quinazoline,
4-(4-chloro-2-fluoroanilino)-7-({1-[(3,3-difluoropyrrolidin-1-yl)acetyl]piperidin-4-yl}methoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-7-(2-{1-[(*N*,*N*-dimethylamino)acetyl]piperidin-4-yl}ethoxy)-6-methoxyquinazoline,
4-(4-bromo-2-fluoroanilino)-7-(2-{1-[(*N*,*N*-dimethylamino)acetyl]piperidin-4-yl}ethoxy)-6-methoxyquinazoline,
4-(4-chloro-2-fluoroanilino)-7-({(3*R*)-1-[(*N*,*N*-dimethylamino)acetyl]piperidin-3-yl}methoxy)-6-methoxyquinazoline,
4-(4-Chloro-2-fluoroanilino)-7-({(3*S*)-1-[(*N*,*N*-dimethylamino)acetyl]piperidin-3-yl}methoxy)-6-methoxyquinazoline,
4-(4-bromo-2-fluoroanilino-6-methoxy-7-{3-[(3a*R*,6a*S*)-tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl]propoxy}quinazoline,
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-{2-[(3a*R*,6a*S*)-tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl]ethoxy}quinazoline,
and salts thereof.

14. A compound according to any one of the preceding claims in the form of a pharmaceutically acceptable salt.

15. A process for the preparation of a compound according to claim 1 of the formula I or salt thereof which comprises:

(a) the reaction of a compound of the formula II:



(II)

wherein R^2 and R^3 are as defined in claim 1 and L^1 is a displaceable moiety, with a compound of the formula III:



(III)

wherein R^1 and Z are as defined in claim 1;

(b) the reaction of a compound of the formula IV:



(IV)

wherein Z, R^1 and R^3 are as defined in claim 1 with a compound of formula V:

$$R^5\text{-}L^1 \qquad (V)$$

wherein R^5 is Q^1, Q^{15} or $Q^{21}W^4C_{1-5}$alkyl, X^2 is X^1 or W^3 and L^1 is as defined herein and wherein Q^1, Q^{15}, Q^{21}, W^4, X^1 and W^3 are as defined in claim 1;

(c) the reaction of a compound of the formula VI:



(VI)

with a compound of the formula VIIa-c:

Q^1-X^1-H (VIIa)

Q^{15}-W^3-H (VIIb)

Q^{21}-W^4-C_{1-5}alkyl-X^1-H (VIIc)

(wherein L^1 is as defined herein and R^1, R^3, Z, Q^1, Q^{15}, Q^{21} W^3, W^4 and X^1 are as defined in claim 1);

(d) the deprotection of a compound of the formula VIII:



(VIII)

wherein R^1, R^3 and Z are all as defined in claim 1, and R^6 represents a protected R^2 group wherein R^2 is as defined in claim 1 but additionally bears one or more protecting groups P^2;

(e) the addition of a substituent to a compound of the formula IX:



(IX)

wherein R^1, R^3 and Z are as defined in claim 1, and R^7 represents an R^2 group which has yet to be substituted with its final substituent;

and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

16. A pharmaceutical composition which comprises a compound of the formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

17. Use of a compound of the formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal.

18. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.